Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

alembic pharmaceuticals limited - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablet is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate tablets are contraindicated in patients with: - urinary retention [see warnings and precautions (5.2)] , - gastric retention [see warnings and precautions (5.3)] , - uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5)] , and - in patients who have demonstrated hypersensitivity to the drug [see adverse reactions(6.2)] . pregnancy category c there are no adequate and well-controlled studies in pregnant women. reproduction studies have been performed in mice, rats and rabbits. after oral administration of 14 c-solifenacin succinate to pregnant mice, drug-related material was shown to cross the placental barrier. no embryotoxicity or teratogenicity was observed in mice treated with 1.2 times (30 mg/kg/day) the expected exposure at the maximum recommended human dose [mrhd] of 10 mg. administrati

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - solifenacin succinate, quantity: 5 mg - tablet - excipient ingredients: maize starch; purified talc; lactose monohydrate; hypromellose; magnesium stearate; titanium dioxide; propylene glycol; iron oxide yellow - solifenacin succinate is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - solifenacin succinate, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; maize starch; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - solifenacin succinate is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - solifenacin succinate, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; maize starch; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; macrogol 8000; purified talc; iron oxide red - solifenacin succinate is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - solifenacin succinate, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; maize starch; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - solifenacin succinate is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - solifenacin succinate, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; maize starch; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; macrogol 8000; purified talc; iron oxide red - solifenacin succinate is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - solifenacin succinate, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; maize starch; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - solifenacin succinate is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - solifenacin succinate, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; maize starch; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; macrogol 8000; purified talc; iron oxide red - solifenacin succinate is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - solifenacin succinate, quantity: 10 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate; hypromellose; titanium dioxide; macrogol 6000; purified talc; iron oxide red - solicare is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - solifenacin succinate, quantity: 5 mg - tablet, film coated - excipient ingredients: hypromellose; lactose monohydrate; maize starch; magnesium stearate; titanium dioxide; macrogol 6000; iron oxide yellow; purified talc - solicare is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.